Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417842 · ClinicalTrials.gov registry record
Connect Lung Outcomes With Bronchodilator Use
A clinical trial, sponsored by Pulmonary Critical Care Associates of Baltimore.
- Completed
- Registry status
- 30
- Enrollment target
NCT04417842: Completed study, sponsored by Pulmonary Critical Care Associates of Baltimore.
NCT04417842 is a clinical trial that has completed, run by Pulmonary Critical Care Associates of Baltimore. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04417842 has completed, sponsored by Pulmonary Critical Care Associates of Baltimore.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
To determine the accuracy of the Respimetrix flow-volume monitoring device in measuring the patient's inspiratory capacity as compared to gold-standard measurements of inspiratory capacity on pulmonary function testing. Accuracy will be assessed before and after (A) pulmonary function testing and before and after (B) the administration of an inhaled bronchodilator medication.
Primary Outcome
Validate the Respimetrix device as compared to pulmonary function test
Interventions
- DIAGNOSTIC_TEST Respimetrix flow-volume monitoring device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2022-04-25 |
What the finished NCT04417842 record still lists
NCT04417842 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Respimetrix flow-volume monitoring device is the first listed.
NCT04417842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04417842 about?
NCT04417842 is a clinical study titled "Connect Lung Outcomes With Bronchodilator Use". To determine the accuracy of the Respimetrix flow-volume monitoring device in measuring the patient's inspiratory capacity as compared to gold-standard measurements of inspiratory capacity on pulmonary function testing. Accuracy will be assessed before and after (A) pulmonary function testing and be...
What is the current status of trial NCT04417842?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2020-08-27. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT04417842?
The interventions under investigation include: Respimetrix flow-volume monitoring device (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04417842?
This trial is sponsored by Pulmonary Critical Care Associates of Baltimore, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI